Maskot/DigitalVision via Getty Images Thesis As you know, Protalix Bio Therapeutics ( PLX ) has just announced some news that should serve as a very positive regulatory and clinical milestone for their Fabry disease treatment in Europe. You see, the EMA’s Committee for Medicinal Products for Human Use ( CHMP ) has just issued a positive opinion recommending approval of a dosing regimen of Elfabrio...
Maskot/DigitalVision via Getty Images Thesis As you know, Protalix Bio Therapeutics ( PLX ) has just announced some news that should serve as a very positive regulatory and clinical milestone for their Fabry disease treatment in Europe. You see, the EMA’s Committee for Medicinal Products for Human Use ( CHMP ) has just issued a positive opinion recommending approval of a dosing regimen of Elfabrio, which can take place every-four-weeks (E4W) for stable adult patients. I think this could potentially transform how enzyme replacement therapy is delivered if the European Commission goes on to confirm this decision by March. It would mean that any eligible patients who now need infusions every two weeks could potentially halve their treatment visits, which would be a massive improvement for patients. It would, of course, reduce physical, emotional, and logistical burden whilst still maintaining the same safety and efficacy. Shares traded up about 14% on the news . Now, this opinion is supported by some long-term clinical data from the BRIGHT study and its ongoing label expansion. There is also robust pharmacokinetic and exposure–response modeling to support the decision. Overall, the data suggest that the less frequent regimen can sustain therapeutic drug levels over time. So, beyond just an improved patient quality of life, I think this shift should have much broader implications for healthcare systems by simply decreasing the demand at infusion centres and resource utilisation. On the strategic side of things, this kind of decision should go a long way in strengthening Elfabrio’s competitive position in the Fabry market. It also goes to show how validated Protalix’s plant-cell-based ProCellEx platform is now in terms of manufacturing approaches. Elsewhere, the decision could come with a potential $25 million milestone payment for Protalix upon EC approval. However, keep in mind that so far we’ve only received a positive opinion from the CHMP, which is essentially a rec...
Save my User ID and Password Some subscribers prefer to save their log-in information so they do not have to enter their User ID and Password each time they visit the site. To activate this function, check the 'Save my User ID and Password' box in the log-in section. This will save the password on the computer you're using to access the site. Note: If you choose to use the log-out feature, you wil...
Save my User ID and Password Some subscribers prefer to save their log-in information so they do not have to enter their User ID and Password each time they visit the site. To activate this function, check the 'Save my User ID and Password' box in the log-in section. This will save the password on the computer you're using to access the site. Note: If you choose to use the log-out feature, you will lose your saved information. This means you will be required to log-in the next time you visit our site.